

# Emission during coal gasification

Evaluation of the carcinogenicity and genotoxicity

To: the State Secretary of Social Affairs and Employment  
No. 2019/07, The Hague, May 20, 2019

---

Health Council of the Netherlands



# contents

<b>Samenvatting</b>	<b>4</b>	<b>03 International classification</b>	<b>13</b>
<b>Executive summary</b>	<b>6</b>	3.1 European Commission	14
<b>01 Scope</b>	<b>8</b>	3.2 IARC	14
1.1 Background	9	3.3 The Health Council of the Netherlands	14
1.2 Committee and procedure	9	<b>04 Monitoring</b>	<b>15</b>
1.3 Data	9	4.1 Environmental exposure monitoring	16
1.4 Criteria for classification	9	4.2 Biological exposure monitoring	16
1.5 Quality assessment	10	<b>05 Manufacture and uses</b>	<b>17</b>
<b>02 Identity of the substance</b>	<b>11</b>	5.1 Manufacture	18
2.1 Name and other identifications	12	5.2 Identified uses	18
2.2 Composition of the emission of coal gasification	12	<b>06 Summary of toxicokinetics</b>	<b>19</b>
2.3 Physicochemical properties	12	6.1 Absorption, distribution and elimination	20
		6.2 Toxicokinetics	20



**07 Germ cell mutagenicity 21**

7.1	Summary and relevance of the provided information on (germ cell) mutagenicity	22
7.2	Comparison with the CLP-criteria	25
7.3	Conclusion on classification and labelling for germ cell mutagenicity	26

**08 Carcinogenicity 27**

8.1	Summary and relevance of the provided information on carcinogenicity	28
8.2	Classification for carcinogenicity	30
8.3	Conclusion on classification and labelling for carcinogenicity	31

**Literature 32**

**Annexes 35**

A	IARC evaluation and conclusion	36
B	Details epidemiological studies	38
C	Details animal carcinogenicity studies	45
D	EU Classification criteria on germ cell mutagenicity	49
E	Classification system on carcinogenicity	52
F	Reliability testing of animal and in vitro studies	53
G	Rseliability testing of epidemiological studies	54



# samenvatting

Op verzoek van de Minister van Sociale Zaken en Werkgelegenheid heeft de Gezondheidsraad beoordeeld of de emissie die vrijkomt tijdens kolenvergassing een genotoxisch effect heeft en tot kanker kan leiden, en op basis daarvan een classificatievoorstel opgesteld. Dit advies is tot stand gekomen in de Subcommissie Classificatie carcinogene stoffen van de commissie Gezondheid en beroepsmatige blootstelling aan stoffen. Op [www.gezondheidsraad.nl](http://www.gezondheidsraad.nl) staat informatie over de taken van de subcommissie van de Gezondheidsraad. De samenstelling van de subcommissie is te vinden achterin dit advies.

## Kolenvergassing

Kolenvergassing is een proces waarbij bruin- of steenkool bij hoge temperaturen en druk wordt vergast tot synthesegas. Het synthesegas wordt gebruikt voor energieopwekking en voor de productie van bijvoorbeeld kunststoffen, zoals

kunstmest. Mensen die in fabrieken werken waar kolenvergassing plaats vindt, kunnen blootstaan aan allerlei stoffen die als gevolg van incomplete kolenvergassing vrij kunnen komen, zoals koolteer. Koolteer bevat verschillende polycyclische aromatische koolwaterstoffen, waarvan sommige – zoals benzo(a)pyreen – kankerverwekkend zijn. In dit advies wordt de beroepsmatige blootstelling aan de emissie die vrijkomt tijdens kolenvergassing als geheel in ogenschouw genomen. De individuele stoffen die in die emissie kunnen voorkomen worden niet afzonderlijk beoordeeld.

## Beoordeling genotoxische en kankerverwekkende eigenschappen

De commissie beoordeelt aan de hand van de beschikbare wetenschappelijk literatuur of er aanwijzingen zijn dat een stof of een proces genotoxisch en kankerverwekkend is en hoe groot de bewijskracht daarvoor is. Genotoxische

stoffen met mutagene eigenschappen kunnen het erfelijk materiaal in de cel blijvend veranderen (mutatie of genafwijking). Hierdoor kunnen zij kankerverwekkend zijn. Aan de hand van de bewijskracht doet de commissie vervolgens voorstellen om de stof of proces te classificeren in gevarencategorieën: één die aangeeft hoe groot de bewijskracht is voor mutageniteit in geslachtscellen, en één die aangeeft hoe groot de bewijskracht is voor kankerverwekkend. De categorieën zijn gebaseerd op EU-verordening (EG) 1272/2008.

De commissie is van oordeel dat er voldoende bewijs is voor een associatie tussen beroepsmatige blootstelling aan de emissie die vrijkomt tijdens kolenvergassing en een toegenomen risico op sterfte door in het bijzonder longkanker. Dierexperimenten, waarbij dieren langdurig blootstonden aan monsters van de emissie van kolenvergassing, ondersteunen de bevinding in mensen.



**Advies aan de minister**

Op basis van beperkte gegevens adviseert de commissie om de emissie die vrijkomt tijdens kolenvergassing te classificeren als mutageen in geslachtscellen in categorie 2 (*“reden tot bezorgdheid voor de mens omdat het mogelijk erfelijke mutaties in de geslachtscellen van mensen veroorzaakt”*).

De commissie concludeert verder dat de emissie die vrijkomt tijdens kolenvergassing kankerverwekkend is voor de mens, en adviseert deze emissie te classificeren in categorie 1A (*“bekend dat het kankerverwekkend is voor de mens”*). De kanker wordt veroorzaakt door een stochastisch genotoxisch werkingsmechanisme.



# Executive summary

At request of the Minister of Social Affairs and Employment, the Health Council of the Netherlands assessed whether the emission, which is formed during coal gasification may induce genotoxic effects and may cause cancer, and on this basis, submitted a proposal for a classification. The advice is made by the Subcommittee on Classifying carcinogenic substances of the Dutch Expert Committee on Occupational Safety. On [www.healthcouncil.nl](http://www.healthcouncil.nl), information can be found on the tasks of the Subcommittee. The membership of the Subcommittee is given on the last page of this advisory report.

## Coal gasificatio

Coal gasification is a process in which lignite and black coal is turned into combustible gas under high temperatures and pressure. The

syngas or synthesis gas is used as fuel for electricity generation, and as intermediate in manufacturing chemicals, such as chemical fertilizers. Workers who are involved in coal gasification, can be exposed to the emission, which is formed during coal gasification. The emission exists of a mixture of substances, for instance as a result of incomplete combustion (e.g., coal tar). In the present advisory report, the evaluation accounts for the emission as a whole. Individual substances that can be found in the emission of coal gasification are not considered.

## Assessment of the genotoxicity and carcinogenicity

Based on the available scientific literature, the Committee assesses the potential genotoxic and carcinogenic properties of the substance or

process in question. The Subcommittee recommends classifying the substance or process in two hazard categories, which represent the grade of evidence for mutagenicity in germ cells (a measure for genotoxicity), and for carcinogenicity. The categories are based on the hazard categories set by the European Commission (EU-guideline (EG) 1272/2008).

The Committee is of the opinion that there is sufficient evidence of an association between occupational exposure to the emission, which is formed during coal gasification and increased cancer mortality, in particular lung cancer mortality. In addition, support for the carcinogenic properties comes from animal experiments in which animals were chronically exposed to coal gasification samples.

## Recommendation

Based on limited evidence, the Committee recommends classifying the emission, which is



formed during gasification, as a germ cell mutagen in category 2 (*“concern for humans owing to the possibility that it may induce heritable mutations in the germ cells of humans”*).

Furthermore, the Committee recommends classifying the emission, which is formed during coal gasification, in category 1A (*“known to be carcinogenic to humans”*). The carcinogenicity is caused by a stochastic genotoxic mechanism.



# 01 scope





## 1.1 Background

In the Netherlands a special policy is in force with respect to occupational use and exposure to carcinogenic substances and processes. Regarding this policy, the Minister of Social Affairs and Employment has asked the Health Council of the Netherlands to assess the genotoxic and carcinogenic properties of substances and processes, and to propose a classification.

This report contains the assessment of the genotoxic and carcinogenic properties of the emission, which is formed during (industrial) coal gasification processes. The evaluation accounts for the exposure to the emission as a whole; evaluation of individual substances, which can be present in the emission, and to which workers can be exposed during coal gasification, is not considered.

## 1.2 Committee and procedure

The evaluation is performed by the Subcommittee on Classifying Carcinogenic Substances of the Dutch Expert Committee on Occupational Safety of the Health Council, hereafter called the committee. The membership of the Committee is listed on the last page of this advisory report.

In 2018, the President of the Health Council released a draft of the report for public review. The committee has taken these comments into account in deciding on the final version of the report. The comments, and the

replies by the committee, can be found on the website of the Health Council.

## 1.3 Data

The committee's recommendation is based on scientific data, which are publicly available. The starting points of the committees' reports are, if possible, the monographs of the International Agency for Research on Cancer (IARC). This means that the original sources of the studies, which are mentioned in the IARC-monograph, are reviewed only by the committee when these are considered most relevant in assessing the carcinogenicity and genotoxicity of the substance in question. In the case of coal gasification, such an IARC-monograph is available, of which the summary and conclusion is inserted in Annex A.

Relevant data, which are published after the (latest) publication of the IARC Monograph, were retrieved from the online databases Medline, Toxline, Chemical Abstracts, and RTECS. The last updated online search was in March 2019. The literature search was based on the following key words: "coal gasification", "manufactured gas plant residue" and "coal tar from gas works".

## 1.4 Criteria for classificatio

For the classification on mutagenicity in germ cells the Committee uses standardly the criteria set by the European Parliament and Council on



classification, labelling and packaging (CLP) of substances (Regulation EC No. 1272/2008). Section 3.5 in Annex I of the regulation describes the classification and labelling requirements for individual mutagenic substances and defined mixtures (see Annex D). In exceptional cases, such as in assessing the mutagenic potential of emissions, which are unintentionally produced during work processes, the Committee bases its recommendation on the criteria of the regulation, in combination with expert judgement.

In 2010, the Health Council published a *Guideline to the classification of carcinogenic compounds*, for classifying substances in terms of their carcinogenic properties, and for assessing the genotoxic mode of action.<sup>26</sup> The classification on carcinogenic properties is based on the Globally Harmonized System, which is also used by the European Union for the classification, labelling and packaging of substances and mixtures (Regulation EC 1272/2008, Section 3.6 Carcinogenicity).<sup>25</sup> Annex E shows the classification system for carcinogenic substances, as used by the Committee.

The proposal for a classification is expressed in standard sentences, combined with a category number.

## 1.5 Quality assessment

The Committee evaluates the available data on relevance and quality by using criteria set by others to assess reliability, and by expert judgment. For animal experiments and in vitro assays, the reliability criteria set by Klimisch et al. (1997) are used.<sup>27</sup> For epidemiological studies, the reliability criteria set by Money et al. (2013) are used.<sup>28</sup> A summary of the reliability criteria is given in Annex F and G, respectively. In addition, for the assessment of the carcinogenicity, the Committee used four categories of evidence. These categories are described in the *Guideline to the classification of carcinogenic compounds* (Health Council, 2010, Chapter 6).<sup>26</sup>



# 02 identity of the substance



## 2.1 Name and other identification

Coal gasification is part of a process to produce combustible gas (mixture of mainly hydrogen and carbon monoxide), also mentioned syngas or synthesis gas. See Section 5.1 for further explanation.

## 2.2 Composition of the emission of coal gasification

During coal gasification, workers may be exposed to hydrogen and carbon monoxide, and to waste or by-products, as a result of incomplete combustion of the coal. The emitted waste or by-products include: gases (e.g., hydrogen sulphide, ammonia, hydrogen cyanide); hydrocarbon containing gases, aerosols and residues (e.g., polynuclear aromatic compounds, coal tar), and: mineral particulate residues (ash) and wastes. The type and amount of these waste and by-products emitted in the workplace air during coal gasification vary, due to variations in feed stocks (type of coal), operating temperatures, pressures and residence times.

Coal tar is a waste product that is produced in large quantities during coal gasification. In coal tar, a number of polynuclear aromatic compounds has been identified, some of which are known for its carcinogenic properties (e.g., benzo(a)pyrene).<sup>1-3</sup> In the scientific literature coal tar from coal gasification is denoted as manufactured gas plant residue (MGP), coal tar pitch volatiles, or coal gasification tar residue (CGTR).<sup>1-3</sup>

## 2.3 Physicochemical properties

Since the emission of coal gasification is a complex mixture of substances, no physicochemical properties are specified.



# 03 international classification



### 3.1 European Commission

Not evaluated.

### 3.2 IARC

IARC evaluated the genotoxicity and carcinogenicity of exposure during coal gasification several times, the latest in 2012.<sup>1-3</sup> It concluded that occupational exposure during coal gasification is carcinogenic to humans. Also there is sufficient evidence in experimental animals for the carcinogenicity of coal-tars from gas-works and manufactured gas plant residues. Furthermore, IARC stated that there is strong evidence of a genotoxic mechanism for coal gasification samples based on experiments. IARC considers it highly likely that genotoxicity is the mechanism for the carcinogenic effects of coal gasification emissions, predominantly due to the presence of mutagenic polycyclic aromatic hydrocarbons. Therefore, IARC classified coal gasification in Group 1 (*“sufficient evidence in humans for the carcinogenicity of occupational exposure during coal gasification”*). A summary of the latest evaluation and conclusion by IARC is given in Annex A.

### 3.3 The Health Council of the Netherlands

Not evaluated.



# 04 monitoring



#### 4.1 Environmental exposure monitoring

Since exposure to the emission of coal gasification implies exposure to a complex mixture, a variety of markers may be applied for the measurement of exposure in workplaces. Overall, in the literature no preference for a certain exposure marker is identified. However, in human studies on the carcinogenic potential of occupational exposure during coal gasification, concentrations of single components (benzo(a)pyrene or other polycyclic aromatic hydrocarbons), total hydrocarbons, coal tar pitch volatiles, and total amount or mass of particles, have been used to estimate exposure. These exposure markers are chosen because of their association with cancer development.

#### 4.2 Biological exposure monitoring

Not specified.





# 05 manufacture and uses



## 5.1 Manufacture

The information given below is abstracted from the IARC monographs.<sup>1,3</sup>

Several coal gasification systems have been developed, which can be classified by the heating value of the gas produced, and by the type of gasification reactor. The majority of the gasification systems consists of four operations: coal pretreatment, coal gasification, raw gas cleaning, and gas beneficiation. In this report, only the genotoxic and carcinogenic properties of the emission during coal gasification (step two) is evaluated.

Generally, any coal can be gasified if properly pretreated. Pretreatment operations include drying, partial oxidation, crushing, sizing, and briquetting of fines for feed to fixed bed gasifiers. The coal feed is pulverized for fluid or entrained bed gasifiers. After pretreatment, the coal enters the gasification reactor where it reacts with oxygen and steam to produce a combustible gas. Air is used as the oxygen source for making gas with a lower caloric value (so-called *low-Btu gas*, where Btu stands for British thermal units; one Btu is the heat required to raise the temperature of one pound of water by one degree Fahrenheit). Pure oxygen is used in making gas with higher value (*medium-* and *high-Btu gas*), as inert nitrogen in the air dilutes the heating value of the product. For gasification of coals, fixed bed, fluidised bed, and entrained flow reactors are used.<sup>3</sup> The choice of the appropriate process depends mainly on the fuel used and on the desired gas utilization. If the gas is utilised in a gas and steam

turbine process, fluidised bed and entrained flow processes are particularly suitable, in which gasification occurs at high pressure (at least 25 - 30 bar). Entrained flow gasification takes place at considerably higher temperatures above the ash fusion point.

## 5.2 Identify uses

Syngas or synthesis gas is mainly used as fuel for electricity generation. In addition, the gas is used as intermediate resource in manufacturing of chemicals, such as chemical fertilizers.



# 06 summary of toxicokinetics



### 6.1 Absorption, distribution and elimination

Data are available on certain individual substances that can be found in the emission of coal gasification, but no such data are available for the emission as a whole. Since in the present report only the emission as a whole is evaluated, this topic is not further discussed.

### 6.2 Toxicokinetics

The same applies for toxicokinetics.



# 07 germ cell mutagenicity



## 7.1 Summary and relevance of the provided information on (germ cell) mutagenicity

### 7.1.1 Summary of genotoxicity tests in vitro

No studies are available on germ cell genotoxicity.

#### Mutagenicity

Cizmas et al. (2004) determined mutagenic activity of seven fractions of a MGP residue in *Salmonella typhimurium* strain TA98.<sup>4</sup> MGP residue was provided by a single site of the Electric Power Research Institute (Palo Alto, USA). The fractions were obtained by chromatographic fractionation of the MGP residue. The residue and its fractions differed in the presence and the composition of polycyclic aromatic hydrocarbons (PAH). Without metabolic activation, 4 of the 6 fractions tested showed mutagenic activity (see Table 1; fraction F6 not tested). In the presence of metabolic activation, mutagenic activity was observed in 6 of 7 fractions.

#### Clastogenic and aneugenic effects

Currently, no publications are available that address in vitro clastogenic or aneugenic effects (chromosomal aberrations, formation micronuclei, sister chromatid exchanges) of coal gasification samples.

#### Conclusion on genotoxicity

The number of studies on mutagenic and genotoxic activities of coal gasification samples (e.g., MGP) is limited. The results of an in vitro reverse mutation study indicate that MGP has mutagenic properties. No data are available that address in vitro clastogenic or aneugenic activities of whole coal gasification samples.

**Table 1.** Mutations

Reference	Method	Cell type	Concentration range	Results	Remarks and reliability
Cizmas et al. 2004 <sup>4</sup>	Reverse mutation (Ames test)	<i>Salmonella typhimurium</i> strain TA98	MGP fractions: <i>Total PAH (µg/mg fraction):</i> F1 (197), F2 (295), F3 (185), F4 (72), F5 (20), F6 (12), and F7 (31) <i>Carcinogenic PAH (µg/mg fraction; sum of benz[a]anthracene, benzo[b]fluoranthene, benzo[k]fluoranthene, benzo(a)pyrene, chrysene, dibenzo[a,h]anthracene, and indeno[1,2,3-c,d]pyrene):</i> F1 (0.18), F2 (40.16), F3 (89,77), F4 (39.48), F5 (11.03), F6 (2.18) and F7 (0.56)	Positive (more than doubling of number of revertants/plate compared to solvent control): • without metabolic activation (S9): F2, F3, F4, F5 (F6 not tested) • with metabolic activation (S9): in 6 of the 7 fractions (dose-related)	Only one strain tested; no data on cytotoxicity; no positive controls used  Reliability 2 (see Annex F)
			Amount of fraction applied per plate: 0.05, 0.5 and 1.0 mg (solvent dimethyl sulphoxide served as negative control)		



### 7.1.2 Summary of human data relevant for germ cell mutagenicity

No data available.

### 7.1.3 Summary of genotoxicity tests in mammalian somatic or germ cells in vivo

No in vivo studies are available, in which the mutagenic, clastogenic or aneugenic effects of coal gasification samples were tested.

#### *DNA-adducts*

In Table 2 results on DNA-adduct formation are summarized. These studies show that crude MGP or fractions of MGP cause a dose-related

increase in DNA-adducts in the lung, the liver, and the forestomach in mice, which were given MGP in various concentrations in the diet. Analyses of the MGP showed the presence of several types of PAH, among which PAHs with well-known genotoxic and carcinogenic potential. Animal experiments indicate that not only the well-known carcinogenic PAH, but also other constituents in MGP may have induced part of the DNA-adducts. Since it is unknown to which extent the detected DNA adducts interfere with DNA replication or are subject to DNA repair activities, the mere presence of DNA adducts cannot be taken as evidence for mutagenicity.

**Table 2.** Formation of DNA-adducts in animals exposed to MGP

Reference	Study design	Data on exposure	Results	Remarks and reliability (Annex F)
Culp and Beland 1994 <sup>5</sup>	Oral administration in diet for 28 days; male B6C3F1 mice; N = 8/group	0, 0.1, 0.25, 0.5, 1 or 2% MGP in diet (corresponds with 0 to 52.5 mg MGP/day); B[a]P served as positive control (applied in diet at doses of 2.5 - 50 mg/kg diet)  DNA-adducts: <sup>32</sup> P-postlabeling assay	DNA-adduct formation increased with increasing dose, adducts/mg DNA): Lung: 22 up to > 6,776 Liver: 65 up to 3,121 Forestomach: 112 up to ± 1,792  Lower intake of diet found in animals given higher doses of MGP; body weights in higher dose groups were lower compared to no and low-dosed animals. Data are corrected for food consumption	Well-documented experimental set-up; proper use of controls; relevance for mode-of-action; well-performed study  No statistical analyses  Reliability 2



Reference	Study design	Data on exposure	Results	Remarks and reliability (Annex F)
Weyand et al. 1994 <sup>6</sup>	Oral administration using a gel diet system for 91 or 185 days; male and female B6C3F1 mice; N = 2 male and 2 females/group	0, 0.05, 0.25 or 0.5% MGP in diet (corresponding with 0.5 g, 2.5 or 5 g MGP per kg diet); B[a]P served as positive control  DNA-adducts: <sup>32</sup> P-postlabeling technique	Dose-related increase in DNA-adduct formation in the lung and forestomach cells; adduct levels lung higher than in the forestomach.	Well-documented experimental set-up; proper use of controls; relevance for mode-of-action; well-performed study  No statistical analyses  Reliability 2
Weyand et al. 1995 <sup>7</sup>	Oral administration using a gel diet system for 14 days; female A/J mice; N = 10/group	Diets contained 0.25% MGP (corresponds to 5.9 mg MGP/day/ mouse); B[a]P as positive control  DNA-adducts: <sup>32</sup> P-postlabeling assay combined with TLC and HPLC	MGP induced DNA adducts in isolated lung ( $\pm 1.8$ pmol adducts/mg DNA) and to a lesser extent in forestomach cells ( $\pm 0.15$ pmol adducts/mg DNA)	Well-documented experimental set-up study (none-guideline study, not GLP); relevance for mode-of-action  No statistical analyses; no negative controls  Reliability 2
Koganti et al. 2001 <sup>8</sup>	Oral administration in basal gel diet for 14 days; female A/J mice; no data on group size	0.25% MGP in diet (corresponds with 2.5 g MGP per kg diet); ethylene chloride soil extracts served as positive control  DNA-adducts: <sup>32</sup> P-postlabeling assay	DNA adduct formation found in lung cells  In MGP samples various PAH were found.  No statistical analyses performed	Well-documented experimental set-up study (none-guideline study, not GLP); proper use of controls; relevance for mode-of-action; well-performed study  Reliability 2
Cizmas et al. 2004 <sup>4</sup>	Single dermal application (topical; skin area 4 cm <sup>2</sup> ; at back of mouse); female ICR mice; N = 3/group	Crude MGP residue and seven MGP fractions, doses applied 0.48, 1.2, or 3.0 mg/mouse  7H-benzo[c]fluorene (PAH component) served as positive control  DNA-adducts: <sup>32</sup> P-postlabeling assay (cells were harvested 24 hours after dermal application)	A dose-related increase in amount of DNA adducts found in isolated lung and skin (application site) cells  Larger effects found in skin cells than in lung cells	Well-documented experimental set-up (none-guideline study, not GLP); proper use of controls; relevance for mode-of-action; well-performed study  Reliability 2





## 7.2 Comparison with the CLP-criteria

The CLP-criteria (Regulation (EC) 1272/2008, Section 3.5, see Annex D) applies only for individual substances and defined mixtures, and not for emissions, which can be formed during work processes. However, to keep close to the method of CLP in assessing genotoxic properties, the Committee based its present recommendation on these criteria, in combination with expert judgement.

According to the criteria in Annex I of the European regulation No. 1272/2008, classification as a mutagen in category 1 is warranted when positive evidence of *in vivo heritable germ cell* mutagenicity in humans (1A) or mammals (1B) has been reported. For exposure during coal gasification, no data have been found on *in vivo* mutagenicity in human or animal germ cells. Therefore, the committee concludes that there is a lack of evidence to classify the emission during coal gasification in category 1.

In addition, substances may be categorized in 1B if there are “*positive results from in vivo somatic cell mutagenicity tests in mammals, in combination with some evidence that the substance has potential to cause mutations to germ cells*”. The latter may be based on a) “*supporting evidence from mutagenicity or genotoxicity tests in germ cells in vivo*”, or b) “*by demonstrating the ability of the substance or its metabolites to interact with the genetic material of germ cells*”. Currently, no *in vivo*

mutagenicity or other genotoxicity tests have been performed on coal gasification samples.

If substances do not meet the criteria for classification in category 1, they may be classified in category 2 if there is “*positive evidence from experiments in mammals and/or in some cases from in vitro experiments obtained from a) somatic cell mutagenicity tests in vivo, in mammals*”, or b) “*other in vivo somatic cell genotoxicity tests, which are supported by positive results from in vitro mutagenicity assays*”. Moreover, “*substances which are positive in in vitro mammalian mutagenicity tests, and which also show chemical structure activity relationship to known germ cell mutagens, shall be considered for classification as category 2 mutagens*”.

There is limited evidence that coal gasification emission samples are mutagenic *in vitro*. However, in the emission of coal gasification, substances may be found with known mutagenic properties (e.g., coal tar and benzo(a)pyrene). Taking into account these findings, the committee is of the opinion that the emission during coal gasification should be classified in category 2. Most likely the mutagenic activity is caused by a stochastic genotoxic mechanism of action, since coal gas emission samples showed mutagenic activity.



### 7.3 Conclusion on classification and labelling for germ cell mutagenicity

Based on limited evidence, the Committee recommends classifying the emission, which can be formed during coal gasification, as a germ cell mutagen in category 2 (*“concern for humans owing to the possibility that they may induce heritable mutations in the germ cells of humans”*).

In addition, the committee concludes that the genotoxic components which can be found in the emission, which can be formed during coal gasification, may cause cancer by a stochastic genotoxic mechanism.



# 08 carcinogenicity



## 8.1 Summary and relevance of the provided information on carcinogenicity

### 8.1.1 Observations in humans

#### Meta-analysis

Bosetti et al. (2006) performed a meta-analysis to investigate the possible association between jobs with expected high polycyclic aromatic hydrocarbon exposure, including coal gasification workers, and the risk for certain cancer types.<sup>9</sup> The analysis included data from 5 cohort studies in the coal gasification industry (Doll et al. 1972, Manz 1980, Hansen et al. 1986, Gustavsson and Reuterwall 1990, Berger and Manz 1992).<sup>10-14</sup> Details of the meta-analysis and the five cohort studies are given in Annex B. The meta-analysis revealed a statistically significant increase in cancer mortality risk estimates for lung, respiratory tract, bladder and urinary tract cancer, in those working in coal gasification.

*Uncertainties and limitations.* In the meta-analyses, a certain degree of heterogeneity between studies was found. This is not surprising to the committee, because the exposure circumstances in different coal gasification facilities may vary. In addition, the committee noted that no description was given on how the authors assessed the quality of the studies, and to what degree each study contributed to the pooled relative risk estimate. The committee considers the study by Manz (1980) of low quality due to limited reporting.<sup>14</sup> Moreover, the committee noted that

polycyclic aromatic hydrocarbon exposure was mainly based on job title; only in the study by Gustavsson and Reuterwall, some polycyclic aromatic hydrocarbon exposure measurements were made.<sup>12</sup> Furthermore, no sensitivity analyses were performed to account for type of study design, and for smoking habits. In most cohort studies data on smoking habits were not collected or reported. Overall, these uncertainties and limitations weaken the conclusion made in the meta-analysis.

#### Prospective cohort studies

Annex B describes three cohort studies with a prospective design. One is not considered by the committee due to limited reporting. Kawai et al. (1967) and Doll et al. (1972) found a statistically significant positive association between coal gasification work and lung cancer mortality.<sup>11,15</sup> The small study by Kawai et al. (1967) showed also that in the age group of 45 to 56 years, workers with more than 20 years of employment had a statistically significant higher lung cancer death rate than workers from the same age group with 10 to 19 years of employment.

*Uncertainties and limitations.* In none of the studies adjustments were made for smoking habits.

#### Retrospective cohort studies

Part of the retrospective cohort studies were limited in design or reporting (Annex B), including the study by Manz (1980), which was included in the



meta-analysis by Bosetti et al. (2006).<sup>14</sup> These low quality studies were not considered by the committee.

In three studies a statistically significant positive association was found between exposure during coal gasification and, in particular, lung cancer mortality. Martin et al. (2000) reported a positive association only in the group of workers with the highest exposure levels.<sup>16</sup> Hansen et al. (1986) found positive associations for lung cancer and general cancer mortality, but did not find an association when years of employment or latency were taken into account.<sup>13</sup> Among German gas furnace workers, Berger and Manz (1992) found positive associations for all cancer mortality, including lung cancer mortality, stomach cancer mortality, and colon and rectum cancer mortality.<sup>10</sup>

To the contrary, Gustavsson and Reuterwall (1990) did not find any association between exposure during coal gasification and cancer mortality.<sup>12</sup> In this study, exposure levels to benzo(a)pyrene in the Swedish gas production company at the top oven were reported to range between 0.007 and 33  $\mu\text{g}/\text{m}^3$  (1964), and between 0.021 and 1.29  $\mu\text{g}/\text{m}^3$  (1965).<sup>12</sup> The authors remark that these exposure levels are of the same magnitude as in American plants. Begera et al. (1991) reported also on exposure levels.<sup>17</sup> Coal tar pitch volatiles during coal gasification ranged from 1.2 to 22,480  $\text{mg}/\text{m}^3$ ; mean average personal exposure to polycyclic aromatic hydrocarbon was 0.03  $\text{mg}/\text{m}^3$ .<sup>17</sup> However, the documentation is too limited to conclude whether these exposure levels could have induced an excess of lung cancer in gas workers.

*Uncertainties and limitations.* Most studies did not account for tobacco smoking, whereas this may seriously influence the outcome of lung cancer and bladder cancer risk estimates. However, Gustavsson and Reuterwall (1990) reported that the percentage of smokers among coal gasification workers and people living in large cities did not differ, and, therefore, suggested that smoking habits did not influence the outcomes for total mortality.<sup>12</sup> Martin et al. (2000) suggested that tobacco smoking had no or only a weak effect on cancer risk estimates, because smoking status is often related to socio-economic status, and the reference group was a reflection of the workers group.<sup>16</sup> Berger and Manz (1992) performed a subanalysis for stomach, colon and rectum cancer, comparing data from smokers with non-smokers (gas furnace workers).<sup>10</sup> For stomach cancer, a positive association was found for smokers, but not for non-smokers, whereas for colon and rectum cancer this was the other way around. The authors noted the imprecision of the risk estimates for colon and rectum cancer, because of the low frequencies of the observed and expected cases. Overall, the committee concludes that smoking status may have influenced the outcomes to a minor degree.

### **Conclusion observations in humans**

Several cohort studies showed some evidence of a positive association between occupational exposure during coal gasification and lung cancer mortality, despite the variation in working and exposure conditions among the various coal gasification facilities. Also cancer at other sites of the



body, such as in the bladder and stomach, have been reported. These data indicate that exposure to emissions of coal gasification is likely to result in cancer at first site of contact (the lungs), and that it may result in development of cancer at distant sites. The observed associations are most likely influenced to a minor degree by confounding factors, such as smoking. In conclusion, the committee is of the opinion that there is sufficient evidence of an association between occupational exposure during coal gasification and increased cancer mortality, in particular lung cancer mortality.

### 8.1.2 Animal carcinogenicity studies

In animal experiments various routes of exposure were used (see Annex C). None of these studies met the current OECD guidelines for assessing carcinogenicity. At least two animal studies are of sufficient quality to be evaluated, of which a description is given below.

The first is the German inhalation study by Rittinghausen et al. (1997).<sup>18</sup> As shown in Annex C, female mice developed lung tumours (squamous cell carcinomas) due to inhalation of coal gasification aerosol samples, or after consuming diets to which tar/pitch condensation products (from coal gasification sites) were included. No description or analytical data on the aerosols were reported, but the aerosols are considered to be related to exposure during coal gasification. No data were presented on general toxicity, and on the development of tumours at other sites in the body.

In the second study, Culp et al. (1998) fed female mice diets containing coal tar, which was obtained from coal gasification plant sites.<sup>19</sup> In the highest exposure groups, histopathologic analyses revealed that these mice developed tumours in the lungs (adenomas and/or carcinomas), the liver (adenomas and/or carcinomas), the forestomach (papillomas and/or carcinomas), and in the small intestines (adenocarcinomas). The authors also noted that in these groups the survival rate was very low and that the animals had on average lower body weights and food intake compared to the control group. Mice, which were given coal tar mixed from seven plant sites showed statistically significant dose-related increase in number of tumour bearing animals.

Although other animal studies are of low quality, they give some support that coal tar or MGP, obtained from coal gasification sites, may induce tumours in the lungs, forestomach, and in the liver of mice (Weynand et al. 1995, Rodriguez et al. 1997).<sup>7,20</sup>

Based on the inhalation study by Rittinghausen et al. (1997) and the oral study by Culp et al. (1998), the committee concludes that there is sufficient evidence that exposure to coal gasification samples causes cancer in mice.

## 8.2 Classification for carcinogenicity

Several cohort studies among workers in coal gasification processes show a positive association between exposure to the emission, which is formed during coal gasification, and cancer-related mortality, in particular lung



cancer mortality. Other types of cancer observed include liver, stomach and skin cancer. Support for the carcinogenic properties of the emission of coal gasification samples comes from animal studies. Mice, which were chronically exposed to coal tar products of coal gasification by the diet or by inhalation, developed cancer at several sites of the body, such as in the lungs, the liver and the forestomach. Based on these findings, and according to the criteria set by the Health Council (see Annex E), the emission, which is formed during coal gasification, should be classified as “*known to be carcinogenic to humans*”, which corresponds to classification in category 1A.

### 8.3 Conclusion on classification and labelling for carcinogenicity

The committee recommends classifying the emission, which is formed during coal gasification, in category 1A (“*known to be carcinogenic to humans*”).



# literature





- <sup>1</sup> International Agency for Research on Cancer. *Polynuclear aromatic compounds, Part 3, industrial exposures in aluminium production, coal gasification, coke production, and iron and steel founding*. IARC (WHO), Lyon, France, 1984; Monograph 34, pages 65-100.
- <sup>2</sup> International Agency for Research on Cancer. *Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42*. IARC (WHO), Lyon, France, 1987; Supplement 7, pages 173-174.
- <sup>3</sup> International Agency for Research on Cancer. *Coal Gasification*. IARC (WHO), Lyon, France, 2012; Monograph 100F, pages 145-152.
- <sup>4</sup> Cizmas L, Zhou GD, Safe SH, McDonald TJ, Zhu L and Donnelly KC. *Comparative in vitro and in vivo genotoxicities of 7H-benzo[c]fluorene, manufactured gas plant residue (MGP), and MGP fractions*. Environ Mol Mutagen 2004; 43(3): 159-68.
- <sup>5</sup> Culp SJ and Beland FA. *Comparison of DNA adduct formation in mice fed coal tar or benzo[a]pyrene*. Carcinogenesis 1994; 15(2): 247-52.
- <sup>6</sup> Weyand EH, Wu Y, Patel S and Goldstein L. *Biochemical effects of manufactured gas plant residue following ingestion by B6C3F1 mice*. J Toxicol Environ Health 1994; 42(1): 89-107.
- <sup>7</sup> Weyand EH, Chen YC, Wu Y, Koganti A, Dunsford HA and Rodriguez LV. *Differences in the tumorigenic activity of a pure hydrocarbon and a complex mixture following ingestion: benzo[a]pyrene vs manufactured gas plant residue*. Chem Res Toxicol 1995; 8(7): 949-54.
- <sup>8</sup> Koganti A, Singh R, Ma BL and Weyand EH. *Comparative analysis of PAH:DNA adducts formed in lung of mice exposed to neat coal tar and soils contaminated with coal tar*. Environ Sci Technol 2001; 35(13): 2704-9.
- <sup>9</sup> Bosetti C, Boffetta PF and La VC. *Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005*. Annals on Oncology 2005; 18(3): 431-46.
- <sup>10</sup> Berger J and Manz A. *Cancer of the stomach and the colon-rectum among workers in a coke gas plant*. Am J Ind Med 1992; 22(6): 825-34.
- <sup>11</sup> Doll R, Vessey MP, Beasley RW, Buckley AR, Fear EC, Fisher RE, et al. *Mortality of gasworkers - final report of a prospective study*. Br J Ind Med 1972; 29(4): 394-406.
- <sup>12</sup> Gustavsson P and Reuterwall C. *Mortality and incidence of cancer among Swedish gas workers*. British Journal of Industrial Medicine 1990; 47: 169-74.
- <sup>13</sup> Hansen KS, Viskum S and Pedersen MS. *[Mortality among gas workers]*. Ugeskr Laeger 1986; 148(10): 610-2.
- <sup>14</sup> Manz A. *Atem- und Harnwege als Lokalisationstellen berufsbedingter (Teer-)Karzinome bei Kokerei- und Rohmetzarbeitern*. VDI-Berichte 1980; 358: 227-35.
- <sup>15</sup> Kawai M, Amamoto H and Harada K. *Epidemiologic study of occupational lung cancer*. Arch Environ Health 1967; 14(6): 859-64.
- <sup>16</sup> Martin JC, Imbernon E, Goldberg M, Chevalier A and Bonenfant S. *Occupational risk factors for lung cancer in the French electricity and gas industry: a case-control survey nested in a cohort of active employees*. Am J Epidemiol 2000; 151(9): 902-12.



- <sup>17</sup> Begraca M, Ukmata H, Morris SC, Canhasi B and Haxhiu MA. *Study of early appearance of skin lesions in coal gasification workers*. Arh Hig Rada Toksikol 1991; 42(3): 287-94.
- <sup>18</sup> Rittinghausen S, Mohr U and Dungworth DL. *Pulmonary cystic keratinizing squamous cell lesions of rats after inhalation/instillation of different particles*. Exp Toxicol Pathol 1997; 49(6): 433-46.
- <sup>19</sup> Culp SJ, Gaylor DW, Sheldon WG, Goldstein LS and Beland FA. *A comparison of the tumors induced by coal tar and benzo[a]pyrene in a 2-year bioassay*. Carcinogenesis 1998; 19(1): 117-24.
- <sup>20</sup> Rodriguez LV, Dunsford HA, Steinberg M, Chaloupka KK, Zhu L, Safe S, et al. *Carcinogenicity of benzo[a]pyrene and manufactured gas plant residues in infant mice*. Carcinogenesis 1997; 18(1): 127-35.
- <sup>21</sup> Christian HA. *Cancer of the lung in employees of a public utility\_A fifteen-year study (1946-1960)*. Journal of Occupational Medicine 1962; 4(3): 133-9.
- <sup>22</sup> Kenneway NM and Kenneway EL. *A study of the incidence of cancer of the lung and larynx*. J Hyg 1936; 36(2): 236-67.
- <sup>23</sup> Wu W. *Occupational cancer epidemiology in the People's Republic of China*. Journal of Occupational Medicine 1988; 30(12): 968-74.
- <sup>24</sup> Brandon JL, Conti CJ, Goldstein LS, DiGiovanni J and Gimenez-Conti IB. *Carcinogenic effects of MGP-7 and B[a]P on the hamster cheek pouch*. Toxicol Pathol 2009; 37(6): 733-40.
- <sup>25</sup> European Union. *Regulation (EC No 1272/2008) of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, Annex I (Classification and labelling requirements for hazardous substances and mixtures), Section 3.5 (Germ cell mutagenicity)*. European Union, <https://echa.europa.eu/regulations/clp/legislation>, last visited: April 23, 2019.
- <sup>26</sup> The Health Council of the Netherlands. *Guideline to the classification of carcinogenic compounds. Guide for classifying compounds in terms of their carcinogenic properties and for assessing their genotoxicity*. The Health Council of the Netherlands, The Hague, report no. A10/07E, 2010.
- <sup>27</sup> Klimisch HJ, Andreae M and Tillmann U. *A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data*. Regul Toxicol Pharmacol 1997; 25(1): 1-5.
- <sup>28</sup> Money CD, Tomenson JA, Penman MG, Boogaard PJ and Jeffrey Lewis R. *A systematic approach for evaluating and scoring human data*. Regul Toxicol Pharmacol 2013; 66(2): 241-7.
- <sup>29</sup> Elm E von, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies*. J Clin Epidemiol 2008; 61(4): 344-9.



# annexes



# A IARC evaluation and conclusion

Occupational exposures during coal gasification are carcinogenic to humans (Group 1).

VOL.: 100F (2012) (p. 145 - 152).<sup>3</sup>

Summary of Data Reported and Evaluation.

## *Exposure data*

Coal gasification is a process by which coal is reacted with oxygen, steam and carbon dioxide by incomplete combustion to release fuel, tars, oils, phenols, heavy hydrocarbons and gas products. In addition to polycyclic aromatic hydrocarbons, workers in coal gasification may be exposed to many compounds, including asbestos, silica, amines, arsenic, cadmium, lead, nickel, vanadium, hydrocarbons, sulfur dioxide, sulfuric acid and aldehydes.

## **Human carcinogenicity data**

Two cohort studies of coal-gasification workers in the United Kingdom (Doll et al., 1972) and Germany (Berger & Manz, 1992), and a case-control study nested within a cohort of French gas- and electricity-

production workers (Martin et al., 2000). In all studies an excess of lung cancer in association with coal gasification was found, which was not likely to be explained by other factors. There was evidence supporting a lung-cancer excess in a historical record-linkage study from the United Kingdom (Kennaway & Kennaway, 1947), in two smaller cohorts (Kawai et al., 1967; Hansen et al., 1986), and a large but inadequately reported Chinese study (Wu, 1988). In addition to lung cancer, the study from the United Kingdom (Doll et al., 1972) showed an excess of bladder cancer, and the German study (Berger & Manz, 1992) showed an excess of cancers of the stomach and colon-rectum.

## *Animal carcinogenicity data*

Crude coal-tars from gas works were shown to induce skin papillomas and carcinomas in mice and rabbits after skin application. Manufactured gas plant residues (MGP) were shown to be carcinogenic in mice after exposure by the feed and after intraperitoneal injection. In these studies, several carcinomas were found, including hepatocellular adenomas, alveolar/bronchiolar adenomas, forestomach papillomas, small intestine adenocarcinomas, as well as haemangiosarcomas and histiocytic sarcomas.

## *Other relevant data*

There is strong evidence from experiments for a genotoxic mode of action for coal gasification samples. Although there are no human studies, it is



highly likely that genotoxicity is the mechanism relevant to the carcinogenic hazards from exposures to emissions of coal gasification.

#### *Evaluation*

There is sufficient evidence in humans for the carcinogenicity of coal gasification. Coal gasification causes cancer of the lung. There is sufficient evidence in experimental animals for the carcinogenicity of coal-tars from gas-works and manufactured gas plant residues. There is strong evidence of a genotoxic mechanism for coal gasification samples based on experimental studies. Although there are no human studies, it is highly likely that genotoxicity is the mechanism for the carcinogenic effects of coal-gasification emissions, predominantly due to the presence of mutagenic polycyclic aromatic hydrocarbons.

#### *Overall evaluation*

Occupational exposures during coal gasification are carcinogenic to humans (Group 1).

#### *Previous evaluations:*

Coal gasification was considered by previous IARC Working Groups in 1983, 1987, and 2005 (IARC, 1984, 1987, 2010).



## B details epidemiological studies

Association between occupational exposure to emissions of coal gasification and cancer development.

### Meta-analysis by Bosetti et al. 2006<sup>9</sup>

Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
<p>5 cohort studies of coal gasification workers (with potential PAH exposure)</p> <p>Details of the individual cohort studies are shown in the list below (indicated as <sup>a</sup>)</p>	<p><i>Search period:</i> Up to December 2005</p> <p><i>Inclusion criteria:</i> workers in industries with high PAH exposure; cohort design; mortality or incidence data on cancer risk (the lungs, the respiratory tract, the bladder, the urinary tract)</p> <p><i>Quality assessment individual studies:</i> not performed or reported</p> <p><i>Meta-analysis:</i> pooled relative risk (RR; calculated as a weighted average of the SMRs, using the inverse of the variance as weight), fixed-effects model, chi-square test for heterogeneity</p>	<p><i>Outcome:</i> positive association between coal gasification work and cancer in the lungs, the respiratory tract, the bladder and the urinary tract</p> <p><i>Order:</i> standardized mortality ratio (SMR), observed/expected no. of cases, pooled RR (95% confidence intervals), p=value for heterogeneity</p> <p><i>Lung cancer (4 cohorts)</i> SMR, 2.14, 188/87.7, 2.29 (1.98-2.64), p&lt;0.0001</p> <p><i>Respiratory tract cancers (5 cohorts)</i> SMR, 2.40, 251/104.7, 2.58 (2.28-2.92), p&lt;0.0001</p> <p><i>Bladder cancer (2 cohorts)</i> SMR, 2.38, 12/5, 2.39 (1.36-4.21), p=0.77</p> <p><i>Urinary tract cancers (3 cohorts)</i> SMR, 2.99, 18/6.02, 3.27 (2.06-5.19), p=0.17</p>	<p>Appropriate design</p> <p>No sensitivity analysis performed; data on smoking habits missing; no quality assessment performed on the individual studies</p> <p>Reliability 2</p>

<sup>a</sup> Data of the study used in meta-analysis by Bosetti et al. (2006).<sup>9</sup>



## Prospective cohort studies

Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Kawai et al. 1967 <sup>15</sup>	Prospective cohort study; Gas generator plant at a steel plant, Japan; follow-up 1953-1965 (up to 12 years); N = 504 gas generator workers, N = 25,760 controls (workers in the same industry but not exposed to tar fumes); participants followed until age of 55 year  Note: gas generator plant was closed in 1953	Exposure based on years of work: 1) <10 years (short) 2) 10-19 years (mid) 3) ≥20 years (high)  Information on lung cancer mortality based on death records; age-specific mortality was computed; statistical analyses by Poisson distribution	<i>Outcome:</i> positive association found for lung cancer mortality; positive association found for years of employment; no associations found for other cancer at other sites of the body  Standardized mortality ratio (obs/exp) of lung cancer: • all: 0.44 (6/0.135), p<0.001 • short: 0.18 (1/0.056), p=0.05 • mid: 0.35 (2/0.057), p=0.001 • long: 1.36 (3/0.022), p<0.001 All lung cancer cases were observed in the age group of 45-54 years  Years of employment (age group 45-56 years old), death rate/100,000 population: 10-19 yrs: 496, 3 death cases, 604.5 persons at risk > 20 yrs or more: 2,688, 5 death cases, 186 persons at riskp p=0.022  No other cancer significantly affected	Appropriate study design, adequate selection of study subjects  Small study; possibility of serious bias (e.g., smoking habits) not taken into account  Reliability 2
Doll et al. 1972 <sup>11 a</sup>	Prospective cohort study; coal carbonizing plants for making gas (4 locations), the UK; follow-up 1953-1965 (up to 12 years); N (A) = 2,444 coal carbonizing process workers, N (C1) = 579 process and maintenance workers in chemical and by-product plant; controls, death rates in male population England & Wales	No data on exposure levels; length of exposure rated as regular, intermittent, or minimal/no exposure  Information on cancer mortality based on death certificate; statistical analyses by Poisson analysis	<i>Outcome:</i> positive association for lung and bladder cancer mortality  Standardized cancer mortality ratio (obs/exp (standardized annual death rates per 1,000 men)):  <i>Coal workers (A)</i> • lung: 1.79 (3.82/2.13), p=0.001, 99 deaths • bladder: 2.35 (0.4/0.17), p=0.03, 10 deaths • skin and scrotum: 6.00 (0.12/0.02), p=0.0, 3 deaths • other cancer: 1.06 (2.70/2.55), 70 death  <i>Maintenance workers (C1)</i> • lung: 0.75 (1.59/2.13), 11 deaths • bladder: 0.76 (0.13/0.17), 1 death • skin and scrotum: 0,00 (0.00/0.02), 0 deaths • other cancer: 0.94 (2.39/2.55), 17 deaths  No subgroup analysis on duration of exposure	Appropriate study design; adequate selection of study subjects  Limited documentation; possibility of serious bias, such as smoking habits, not taken into account  Reliability 2



Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Christian 1962 <sup>21</sup>	Prospective cohort study; public utility, the USA; follow-up 1946-1961 (15 years); N=1,031 gas plant workers (full cohort = 23,571 workers)	No data on exposure levels  Workers were observed for lung cancer development	<i>Outcome:</i> data do not allow a conclusion  During follow-up, 125 lung cancer cases were observed, of which 123 cases were heavy smokers. This corresponds with 35.4 cases per year per 100,000 population (full cohort)  <i>Gas plant workers:</i> • 23 cases/1,031 workers • 149 cases per 100,000 man-year observation (no other data presented)	No clear criteria in the selection study subjects; possibility of serious bias, such as smoking habits not taken into account; no statistical analyses performed  Reliability 3

<sup>A</sup> Data of the study used in meta-analysis by Bosetti et al. (2006).<sup>9</sup>

## Retrospective cohort studies

Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Martin et al. 2000 <sup>16</sup>	Case control survey nested in a retrospective cohort study; national electricity and gas company, France; data retrieved from 1978-1989; 1,400,00 person-years based on male workers employed between 1978-1989 for at least one year; for each case four age-matches controls were randomly selected	No data on exposure levels; MATEX job exposure matrix was used, which is based on occupational groups. The matrix includes quantitative levels of exposure and exposure times.  Lung cancer mortality identified by social security fund of company; for each case of lung cancer 4 age-matched controls from cohort were randomly selected; statistical analyses by conditional logistic regression models, trend odds ratio's	<i>Outcome:</i> only positive association found for lung cancer mortality in the highest exposed group  A total 310 lung cancer cases were registered (mean age at time of diagnosis was 49.9 years, which was identical to that of the controls)  Odds ratio (cases/controls, 95% confidence interval), coal gas production:  <i>Overall (adjusted: no or yes):</i> • no: 1.89 (26/12, 0.93-3.86) • yes: 1.64 (-/-, 0.80-3.40)  <i>Cumulative exposure (percentiles, adjusted):</i> • not exposed: 1.00 (1,176/291, -) • <25 <sup>th</sup> : 1.02 (7/2, 0.21-4.94) • 25 <sup>th</sup> -50 <sup>th</sup> : 1.59 (7/3, 0.39-6.49) • 50 <sup>th</sup> -75 <sup>th</sup> : 0.55 (7/1, 0.07-4.57) • ≥ 75 <sup>th</sup> : 3.87 (5/6, 1.15-12.9) Trend odd ratio: 1.10 (1.01-1.21)	Well-documented study; data were adjusted for serious bias, such as socioeconomic situation, and exposure to asbestos, PCBs, and polychlorinated biphenyls.  Data on smoking habits were not available. Authors remark that smoking habits often are related to socioeconomic status, and therefore expect that this confounding factor is weak or absent  Reliability 1





Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Gustavsson and Reuterwall 1990 <sup>12a</sup>	Retrospective cohort study; coal gas production company, Sweden; data retrieved from 1966-1988 (mortality) and 1966-1983 (cancer incidence); N=295 workers employed for at least one year between 1965 and June 1972, when the coal gasification stopped; reference rates for mortality were based on mortality all man in 'greater Stockholm' or 'employed in Stockholm'	Exposure to B[a]P (top oven, area sampling) measured: 1964: 0.007-33 µg/m <sup>3</sup> 1965: 0.021-1.29 µg/m <sup>3</sup>  Workers were divided into departments (coke ovens, steam and generator central, coke department, byproduct workers, workshop and maintenance workers, outside workers, sample preparation), or by employment period  Expected numbers of deaths based on local death rates among occupationally active men, expected numbers of cancer based on national statistics	<i>Outcome:</i> no associations found  Standardized Mortality Ratio (exp/obs, 95% confidence interval), expected based on 'employed in Stockholm'  <i>Overall:</i> • all malignant tumours: 1,14 (22 /19.3, 0.71-1.72) • lung cancer: 0.82 (4/4.85, 0.22-2.11)  <i>Employment period (years):</i> All malignant tumours 1-29 y: 1.03 (17/16.6, 0.6-1.64) ≥ 30 y: 1.43 (8/5.6, 0.62-2.82) Lung cancer 1-29 y: 0.00 (0/1.3, 0-2.79) ≥ 30 y: 1.41 (2/1.4, 0.17-5.09)  <i>Department:</i> Coke oven department: • All malignant tumours: 1.43 (5 /3.5) • Lung cancer: 0 (0/0.9) Steam and generator department: • all malignant tumours: 2.22 (2/0.95) • lung cancer: 0 (0/0.2) Coke department: • malignant tumours: 2.11 (6/2.8) • lung cancer: 2.84 (2/0.7)	Well-documented study; study subjects adequately selected  Limited number of participants; limited number of cases; possibility of serious bias not taken into account  Authors report that the percentage daily smokers among coal gas workers (52%) were comparable with daily smokers in large cities. Therefore, they stated that excess of causes did not seem to be caused by smoking habits.  Reliability 2
Berger and Manz 1992 <sup>10a</sup>	Retrospective cohort study; Hamburg coke gas plant, Germany; data retrieved for the period 1953-1989; N = 4,908 male workers employed for ≥ 10 years (in the period 1900 to 1989)	No data on exposure levels  <i>Subcohorts based on job titles:</i> (I) gas furnace workers (exposed to high concentrations of coal tar gas, in particular PAH and different heterocyclics; 789 workers)	<i>Outcome:</i> positive association for cancer mortality (all cancers, lung cancer, stomach cancer) in gas furnace workers; non-smokers had no excess risk in stomach cancer mortality  Standardized mortality ratio (obs/exp, 95% confidence interval)  <i>Subcohort I</i> • all cancers: 1.86 (190/102.2, 1.61-2.14) • lung cancer: 2.88 (78/27.1, 2.28-3.59) • stomach cancer: 1.77 (31/1.5, 1.20-2.51) • colon and rectum cancer: 1.84 (13/7.1, 0.98-3.15)	Well-documented study; study subjects adequately selected; serious possibility for bias was taken into account (smoking habits and health worker effect)  Reliability 2



Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
		<p>(II) workers in other parts of the plant occasionally exposed to several chemicals, 3,401 workers)</p> <p>(III) white-collar workers (no exposure, 718 workers)</p> <p>Mortality and cause of death from company and personal medical records; Internal control = white-collar workers, external controls = calendar period-, age-, and cause-specific death rates of males for Germany (from 1952-1989); statistical analyses by likelihood-ratio-test, chi-square test for homogeneity, confidence intervals by Poisson distribution; smoking habits taken into account</p>	<p><i>Subcohort II</i></p> <ul style="list-style-type: none"> <li>• all cancers: 0.96 (384/399.6, 0.87-1.06)</li> <li>• lung cancer: 0.96 (102/106.3, 0.78-1.17)</li> <li>• stomach cancer: 1.13 (72/63.7, 0.88-1.42)</li> <li>• colon and rectum cancer: 1.70 (48/ 28.3, 1.25-2.25)</li> </ul> <p><i>Subcohort III</i></p> <ul style="list-style-type: none"> <li>• all cancers: 0.56(59/104.9, 0.43-0.73)</li> <li>• lung cancer: 0.45 (12/26.2, 0.23-0.79)</li> <li>• stomach cancer: 0.57 (10/17.5, 0.27-1.05)</li> <li>• colon and rectum cancer: 0.92 (7/7.6, 0.37-1.90)</li> </ul> <p><i>Smoking in subcohort I</i></p> <ul style="list-style-type: none"> <li>• stomach cancer: no: 1.40 (3/2.15, 0.29-4.09), N=103 yes: 2.56 (22/8.61, 1.60-3.87, N=546)</li> <li>• colon and rectum cancer: no: 4.35 (4/0.92, 1.18-1,11), N=103 yes: 1.68 (8/4.76, 0.73-3.31), N=546</li> </ul>	
Hansen et al. (1986) <sup>13a</sup>	Cohort; Denmark; 47 male workers employed >1 year any time between 1911-1970; 141 non-exposed age-matched controls, selected from population registers; period of follow-up, no data	<p>No data on exposure levels</p> <p>Mortality all causes, all cancers, and lung cancer</p>	<p><i>Outcome:</i> positive association for lung cancer and general cancer mortality; no association with year of employment or latency</p> <p>Standardized mortality ratio (SMR) (95% confidence interval), cases/controls</p> <p><i>Lung cancer</i> SMR 8.9 (-), 7/6 Odds ratio 3.94, p=0.01</p> <p><i>Other cancers</i> SMR - (-), 7/8 Odds ratio, 2.91, p=0.02</p>	<p>Small study, appropriate design</p> <p>No data on smoking habits or other confounding factors</p> <p>Reliability 2</p>



Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Begraca et al. 1991 <sup>17</sup>	Retrospective cohort study; Coal gasification plant, Kosovo; data retrieved from 1971-1986; study performed in 1986; N=622 male workers (ever been employed through 1980); N=442 reference population (open-pit lignite miners)	<p>Exposure data collected several days between 1981-1985:</p> <ul style="list-style-type: none"> <li>• area exposure was highly variable (range coal tar pitch volatile, 1.2-22,480 mg/m<sup>3</sup>)</li> <li>• mean personal exposure (mg/m<sup>3</sup>, range): benzene, 0.16 (&lt;0.02-20.0); total hydrocarbons, 0.42 (&lt;0.02-43.0); PAH, 0.03 (&lt;0.002-0.62); total particles, 0.22 (&lt;0.01-10.0)</li> <li>• there was extensive surface contamination (no details given)</li> </ul> <p>Data based on employment and medical records of periodical occupational medical checks; only skin cancer was addressed;</p> <p>Average age: 34.2 years; average duration of experience: 10 years</p>	<p><i>Outcome:</i> data do not allow a conclusion</p> <p>Incidence of skin cancer (rate, age adjusted):</p> <ul style="list-style-type: none"> <li>• gas workers: 1.9/1,000 (13 cases)</li> <li>• reference population: 1.5/1,000 (7 cases)</li> </ul>	<p>Limited documented study; small study; limited data on statistical methodology</p> <p>Data on smoking habits reported (28% in workers, 31% in reference group), but unclear whether these are taken into account in the analysis</p> <p>Reliability 3</p>
Kennaway and Kennaway 1936 <sup>22</sup>	Retrospective mortality study; gas industry, the UK; N=18,275 death certificates from England and Wales analysed for the years 1921-1932; annual total data for cases in women used for comparison	<p>No data on exposure levels; job history was based on death certificates</p> <p>Death certificates revealed 8,808 cases of lung cancer mortality and 9,472 cases of larynx cancer mortality</p>	<p><i>Outcome:</i> data do not allow a conclusion</p> <p>Gas stokers and coke-oven chargers (estimated population 12,818)</p> <p>Standardized cancer mortality ratio (obs/exp):</p> <ul style="list-style-type: none"> <li>• lung: 3,42 (37/10.8)</li> <li>• larynx: 1,86 (20/10.7)</li> </ul>	<p>Appropriate study design, but limited reporting and analyses</p> <p>No statistical analyses performed; no data on smoking habits or other possible confounders</p> <p>Reliability 3</p>



Reference	Study design and population	Data on exposure and health assessment	Results	Remarks and reliability (Annex G)
Wu et al. 1988 <sup>23</sup>	Retrospective cohort study; six coal gas plants, China; data retrieved from 1971-1981; N=3,107 workers; reference population were workers in a steel rolling mill	No data on exposure levels  Death cases identified among workers who were employed in 1971, and who died during the next 10 years	<i>Outcome:</i> data do not allow a conclusion  Standardized Risk Ratios (confidence interval): • all causes: 1.29 (1.16-1.44), 234 deaths • all cancer: 1.73 (1.46-2.02), 109 deaths • lung cancer: 3.66 (2.36-5.43)	Data from secondary source, and listed as short summary: IARC 2012 <sup>3</sup>  No other data available  Reliability 4
Manz (1980) <sup>14 a</sup>	Cohort; Germany; 5.405 workers in one company; period of employment: 1953-1977; period of follow-up: no data	No data on exposure levels  Mortality	<i>Outcome:</i> data do not allow a conclusion  Standardized mortality ratio (SMR) (95% confidence interval)  <i>Respiratory tract cancer</i> SMR 3.7, 63 death cases <i>Urinary tract cancer</i> SMR 6.1, 6 death cases	Data obtained from secondary source: Bosetti et al. (2006) <sup>9</sup>  No other data available  Reliability 4

<sup>a</sup> Data of the study used in meta-analysis by Bosetti et al. (2006).<sup>9</sup>



# C details animal carcinogenicity studies

Cancer development in animals, which are exposed to waste products of the coal gasification process.

## Inhalation studies

Reference	Animal species	Data on exposure and effect endpoints Xpo = exposure period; Xpe = exposure + observation period	Results	Remarks and reliability (Annex F)
Rittinghausen et al. 1997 <sup>18</sup> Germany	Female CrI:[WI] BR Wistar rats; N=72/group	Tar/pitch condensation aerosol (source unknown) of several B[a]P concentrations: 0 (clean air), 20 µg B[a]P /m <sup>3</sup> , 50 µg B[a]P /m <sup>3</sup> , or 125 µg B[a]P/m <sup>3</sup>  <i>Exposure scenario 1:</i> 17 h/day, 5 days/week for 30 months; Xpo=10 months; Xpe=30 months  <i>Exposure scenario 2:</i> Exposure: 18 h/day, 5 days/week for 30 months; Xpo=20 months; Xpe=30 months  Histopathological examination on lung lesions	Number of tumour bearing animals (in order of increasing exposure)  <i>Exposure scenario 1:</i> <ul style="list-style-type: none"> <li>Pulmonary cystic keratinizing squamous cell carcinoma: 0/72, 0/72, 23/72*, 38/72*</li> <li>Pulmonary keratinizing squamous cell carcinoma: 0/72, 1/72, 4/72, 3/72</li> <li>Total number of pulmonary squamous cell carcinomas: 0, 1/72, 27/72*, 41/72*</li> </ul> <i>Exposure scenario 2:</i> <ul style="list-style-type: none"> <li>Pulmonary cystic keratinizing squamous cell carcinoma: 0/72, 19/72*, 63/72*, 62/72*</li> <li>Pulmonary keratinizing squamous cell carcinoma: 0/72, 4/72, 5/72, 4/72</li> <li>Total number of pulmonary squamous cell carcinomas: 0, 23/72*, 68/72*, 66/72*</li> </ul> <p>* statistically different from control, p&lt;0.001</p>	Sufficient number of animals; sufficient duration of exposure  Histopathological examination limited to the lungs; no data on: non-carcinogenic effects, number of tumours per animal; early mortality, trends in food consumption and body weight  Reliability 2



### Oral administration

Reference	Animal species	Data on exposure and effect endpoints Xpo = exposure period; Xpe = exposure + observation period	Results	Remarks and reliability (Annex F)
Culp et al. 1998 <sup>19</sup> The USA	Female B6C3F1 mice; N=48/group	<p>Coal tar (from coal gasification plant waste sites) added to the diet:</p> <ul style="list-style-type: none"> <li>• <i>Mixture 1</i>: composite of coal tar from seven sites (0.1% in diet corresponds with 2.2 ppm B[a]P); 0 (solvent, control), 0.01, 0.03, 0.1, 0.3, 0.6 and 1.0% in diet</li> <li>• <i>Mixture 2</i>: composite of coal tar from two of the seven sites + one site with known high level of B[a]P content in coal tar (0.1% in diet corresponds with 3.7 ppm B[a]P): 0 (solvent, control), 0.03, 0.1 and 0.3% in diet</li> <li>• - <i>Positive control</i>: B[a]P only</li> </ul> <p>* Food intake is estimated at 0.35 g/day; average body weight estimated to be 25 gram. Doses in diet correspond to approximately 1.4, 4.2, 14, 42, 84 and 420 mg B[a]P/kg bw/day</p> <p>Exposure on daily basis for 2 years; Xpe=2 years, Xpo=2 years</p> <p>Gross pathology and histopathology performed on the liver, lungs, small intestines, stomach, tongue and esophagus Full histopathology performed (except in mixture 1 group, 0.03%)</p>	<p><i>Percentage survival whole treatment period (in order of increasing exposure):</i> <i>Mixture 1</i>: 65, 71, 69, 63, 21, 0, 0 <i>Mixture 2</i>: 65, 65, 65, 15</p> <p>In highest dose groups significant decrease in food consumption. Also lower body and organ weight reported.</p> <p><i>Number of tumour bearing animals</i> (in order of increasing exposure; * p&lt; 0.05)</p> <p><i>Mixture 1 (all exposure levels):</i></p> <ul style="list-style-type: none"> <li>• Liver hepatocellular adenomas and/or carcinomas: 0/47, 4/48, 2/46, 3/48, 14/45*, 1/42, 5/43</li> <li>• Lung (alveolar/bronchiolar) adenomas and/or carcinomas: 2/47, 3/48, 4/48, 4/48, 27/47, 25/47*, 21/45*</li> <li>• Forestomach papillomas and/or carcinomas: 0/47, 2/47, 6/45, 3/47, 14/46*, 15/45*, 6/41</li> <li>• Small intestine adenocarcinomas: 0/47, 0/46, 0/45, 0/47, 0/42, 22/36*, 36/41*</li> <li>• Haemangiosarcomas: 1/48, 0/48, 1/48, 1/48, 11/48*, 17/48*, 1/45</li> <li>• Histiocytic sarcomas: 1/48, 0/48, 0/48, 1/48, 7/48, 5/48, 0/45</li> <li>• Sarcomas: 1/48, 4/48, 3/48, 2/48, 7/48, 1/48, 2/45</li> </ul> <p>For all tumour types a dose significant trend was observed (p = 0.003-0.00001)</p> <p><i>Mixture 2 (0.03%, 0.3% and 0.6%):</i></p> <ul style="list-style-type: none"> <li>• Liver hepatocellular adenomas and/or carcinomas: 7/47, 4/47, 10/45*</li> <li>• Lung (alveolar/bronchiolar) adenomas and/or carcinomas: 4/48, 10/48*, 23/47*</li> <li>• Forestomach papillomas and/or carcinomas: 3/47, 2/47, 13/44*</li> <li>• Small intestine adenocarcinomas: 0/47, 0/47, 1/37</li> <li>• Haemangiosarcomas: 1/48, 4/48, 17/48*</li> <li>• Histiocytic sarcomas: 3/48, 2/48, 11/48*</li> <li>• Sarcomas: 0/48, 4/48, 5/48</li> </ul> <p>Not tested for dose related trends</p>	<p>Well-documented study; data included food consumption, body weight, organ weights and percentage of survival; sufficient number of animals per group</p> <p>No data on general toxicity; no data on coal tar consumption expressed as mg/kg bw/day; only female mice tested</p> <p>Reliability 2</p>



Reference	Animal species	Data on exposure and effect endpoints Xpo = exposure period; Xpe = exposure + observation period	Results	Remarks and reliability (Annex F)
Weyand et al. 1994 <sup>6</sup> The USA	Male and female B6C3F1 mice; N=12/sex/group	0.0% (control) or 0.5% MGP* residue in basal gel diet; 0.005% B[a]P in diet served as positive control  * Intake of 0.5% MGP: B[a]P content in diet=1,560 mg/kg bw; food intake=5.7 g/d/mouse (females). Based on average body weight of 25g during the study, MGP intake is estimated at 1,140 mg B[a]P/kg bw/day (for males: 1,480 mg/kg bw/day)  Exposure on daily base for 185 days; Xpo and Xpe=185 days;  All organs histopathologically examined for gross lesions	No signs of acute toxicity or early mortality. Mean body weight in highest dosed group was lower compared to non-exposed animals.  Number of tumour bearing animals (in order of negative control, positive control and 0.5% MGP): • Forestomach, squamous-cell carcinoma: Male, 0/10, 0/10, 1/10; Female, no data; No correlation with exposure to MG  Preneoplastic lesions: low and sporadic incidence, no correlation with exposure to MGP	Number of animals too low for statistical robustness of the outcome; exposure duration too short for tumour development; only one dose of MGP tested  Reliability 3
Weyand et al. 1995 <sup>7</sup> The USA	Female A/J mice; N=30/group	0.0% (control), 0.10% or 0.25% MGP* residue in basal gel diet; 11 and 67 mg B[a]P per mouse served as positive control (administered by a single intraperitoneal injection)  * Based on an average body weight of 25 g during the study, the exposures correlate to 0, 100 and 236 mg B[a]P/kg bw/day  Exposure on daily base for 260 days; Xpo and Xpe = 260 days  Histopathologic examination of the lungs and stomach on tumour development	Mice fed gel diet without MGP (control group) consumed less food and had lower body weights (authors did not have an explanation for this observation). Mortality rates ranged from 3 to 30% in control, MGP fed, and B[a]P exposed animal groups.  Number of tumour bearing animals (in order of increasing exposure): lung tumours: 4/21, 19/27*, 29/29* (B[a]P: 14/27*), * p<0.05 forestomach tumours: 0/21, 0/27, 0/29 (B[a]P: 27/27*), * p<0.05  Number of tumours per mouse (multiplicity; in order of increasing exposure): lung tumours: 0.19±0.09, 1.19±0.21*, 12.17±0.14* (B[a]P: 0.59±0.12), * p<0.05 forestomach tumours: 0, 0, 0 (B[a]P: 4.22±0.41*), * p<0.05	Duration of study too short for maximum tumour development; limited histopathological examination; tumour types not specified; in negative control group early mortality was noted Study not reliable  Reliability 3



## Dermal application

Reference	Animal species	Data on exposure and effect endpoints Xpo = exposure period; Xpe = exposure + observation period	Results	Remarks and reliability (Annex F)
Brandon et al. 2009 <sup>24</sup> The USA	Male Syrian hamsters; N=4/group	MGP residue applied at doses of 50% and 100% solution in mineral oil; mineral oil served as negative control; 2% B[a]P and 0.5% DMBA served as positive controls (applied in mineral oil)  200 µL applied topically into the right cheek pouch  Exposure 3 times per week: Xpo and Xpe 12, 16, 20, 28 and 32 weeks;  Histopathologic examination of the right cheek pouch	No tumours in cheek pouch (only diffuse epithelial hyperplasia at 32 weeks)	Limited experimental set-up: only cheek pouch examined; small number of animals; no data on general toxicity  Reliability 3

## Intraperitoneal injection

Reference	Animal species	Data on exposure and effect endpoints Xpo = exposure period; Xpe = exposure + observation period	Results	Remarks and reliability (Annex F)
Rodriguez et al. 1997 <sup>20</sup> The USA	Male and female B <sub>6</sub> C <sub>3</sub> F <sub>1</sub> mice (infant, 15 days old); N=30/group	Single injection of: • MGP-4*, 1,140 mg/kg bw • MGP-M7*, 285, 570 and 1,140 mg/kg bw • B[a]P served as positive control  * MGP-4 represents coal tar from a single site, MGP-M7 is a residue composite of 7 sites  Xpo: 26, 39 and 52 weeks  Histopathologic examination on the lung, liver and forestomach tissues	No forestomach tumour found in any group. Few pulmonary tumours were observed, but no correlation with exposure to MGP.  Liver tumours (data presented are from week 52; in order of corn oil only (control), MGP-4, MGP-M7 low, medium and high, B[a]P): <i>Number of tumour bearing animals:</i> Males: 3/63, 12/28, 4/34, 8/32, 17/29, 19/24 Females: no treatment related tumours <i>Number of tumours per mouse:</i> Males: 1.0, 1.7, 1.2, 1.4, 1.8, 2.5 Females: no treatment related tumours	Irrelevant route of exposure for humans; no statistical analyses performed; no whole body histopathological examination; no data on general toxicity  Reliability 3





## D EU Classification criteria on germ cell mutagenicity

Source: Regulation (EC No. 1272/2008) of the European Parliament and of the Council of 10 August 2009 on classification, labelling and packaging (CLP) of substances, Annex I “Classification and labelling requirements for hazardous substances and mixtures”, Section 3.5.<sup>25</sup>

### 3.5 Germ cell mutagenicity

#### 3.5.1. Definitions and general considerations

3.5.1.1. *A mutation means a permanent change in the amount or structure of the genetic material in a cell. The term ‘mutation’ applies both to heritable genetic changes that may be manifested at the phenotypic level and to the underlying DNA modifications when known (including specific base pair changes and chromosomal translocations). The term ‘mutagenic’ and ‘mutagen’ will be used for agents giving rise to an increased occurrence of mutations in populations of cells and/or organisms.*

3.5.1.2. *The more general terms ‘genotoxic’ and ‘genotoxicity’ apply to agents or processes which alter the structure, information content, or segregation of DNA, including those which cause DNA damage by interfering with normal replication processes, or which in a non-physiological manner (temporarily) alter its replication. Genotoxicity test results are usually taken as indicators for mutagenic effects.*

#### 3.5.2. Classification criteria for substances

3.5.2.1. *This hazard class is primarily concerned with substances that may cause mutations in the germ cells of humans that can be transmitted to the progeny. However, the results from mutagenicity or genotoxicity tests in vitro and in mammalian*

*somatic and germ cells in vivo are also considered in classifying substances and mixtures within this hazard class.*

3.5.2.2. *For the purpose of classification for germ cell mutagenicity, substances are allocated to one of two categories as shown in Table 3.5.1*

#### 3.5.2.3 Specific considerations for classification of substances as germ cell mutagens

3.5.2.3.1. *To arrive at a classification, test results are considered from experiments determining mutagenic and/or genotoxic effects in germ and/or somatic cells of exposed animals. Mutagenic and/or genotoxic effects determined in in vitro tests shall also be considered.*

3.5.2.3.2. *The system is hazard based, classifying substances on the basis of their intrinsic ability to induce mutations in germ cells. The scheme is, therefore, not meant for the (quantitative) risk assessment of substances.*

Table 3.5.1. Hazard categories for germ cell mutagens

Categories	Criteria
CATEGORY 1:	Substances known to induce heritable mutations or to be regarded as if they induce heritable mutations in the germ cells of humans. Substances known to induce heritable mutations in the germ cells of humans.
Category 1A:	The classification in Category 1A is based on positive evidence from human epidemiological studies. Substances to be regarded as if they induce heritable mutations in the germ cells of humans.
Category 1B:	The classification in Category 1B is based on: <ul style="list-style-type: none"> <li>— positive result(s) from in vivo heritable germ cell mutagenicity tests in mammals; or</li> <li>— positive result(s) from in vivo somatic cell mutagenicity tests in mammals, in combination with some evidence that the substance has potential to cause mutations to germ cells. It is possible to derive this supporting evidence from mutagenicity/ genotoxicity tests in germ cells in vivo, or by demonstrating the ability of the substance or its metabolite(s) to interact with the genetic material of germ cells; or</li> <li>— positive results from tests showing mutagenic effects in the germ cells of humans, without demonstration of transmission to progeny; for example, an increase in the frequency of aneuploidy in sperm cells of exposed people.</li> </ul>



CATEGORY 2:	<p>Substances which cause concern for humans owing to the possibility that they may induce heritable mutations in the germ cells of humans. The classification in Category 2 is based on:</p> <ul style="list-style-type: none"> <li>— positive evidence obtained from experiments in mammals and/or in some cases from in vitro experiments, obtained from: <ul style="list-style-type: none"> <li>— somatic cell mutagenicity tests in vivo, in mammals; or</li> <li>— other in vivo somatic cell genotoxicity tests which are supported by positive results from in vitro mutagenicity assays.</li> </ul> </li> </ul> <p><i>Note:</i> Substances which are positive in in vitro mammalian mutagenicity assays, and which also show chemical structure activity relationship to known germ cell mutagens, shall be considered for classification as Category 2 mutagens.</p>
-------------	--

3.5.2.3.3. *Classification for heritable effects in human germ cells is made on the basis of well conducted, sufficiently validated tests, preferably as described in Regulation (EC) No 440/2008 adopted in accordance with Article 13(3) of Regulation (EC) No 1907/2006 ('Test Method Regulation') such as those listed in the following paragraphs. Evaluation of the test results shall be done using expert judgement and all the available evidence shall be weighed in arriving at a classification.*

3.5.2.3.4. *In vivo heritable germ cell mutagenicity tests, such as:*

- *rodent dominant lethal mutation test;*
- *mouse heritable translocation assay.*

3.5.2.3.5. *In vivo somatic cell mutagenicity tests, such as:*

- *mammalian bone marrow chromosome aberration test;*
- *mammalian erythrocyte micronucleus test.*

3.5.2.3.6. *Mutagenicity/genotoxicity tests in germ cells, such as:*

*(a) mutagenicity tests:*

- *mammalian spermatogonial chromosome aberration test;*
- *spermatid micronucleus assay;*

*(b) Genotoxicity tests:*

- *sister chromatid exchange analysis in spermatogonia;*
- *unscheduled DNA synthesis test (UDS) in testicular cells.*

3.5.2.3.7. *Genotoxicity tests in somatic cells such as:*

- *liver Unscheduled synthesis test (UDS) in vivo;*
- *mammalian bone marrow Sister Chromatid Exchanges (SCE);*

3.5.2.3.8. *In vitro mutagenicity tests such as:*

- *in vitro mammalian chromosome aberration test;*
- *in vitro mammalian cell gene mutation test;*
- *bacterial reverse mutation tests.*

3.5.2.3.9. *The classification of individual substances shall be based on the total weight of evidence available, using expert judgement (See 1.1.1). In those instances where a single well-conducted test is used for classification, it shall provide clear and unambiguously positive results. If new, well validated, tests arise these may also be used in the total weight of evidence to be considered. The relevance of the route of exposure used in the study of the substance compared to the route of human exposure shall also be taken into account.*



### 3.5.3 Classification criteria for mixtures

3.5.3.1. Classification of mixtures when data are available for all ingredients or only for some ingredients of the mixture

3.5.3.1.1. The mixture shall be classified as a mutagen when at least one ingredient has been classified as a Category 1A, Category 1B or Category 2 mutagen and is present at or above the appropriate generic concentration limit as shown in Table 3.5.2 for Category 1A, Category 1B and Category 2 respectively.

Table 3.5.2. Generic concentration limits of ingredients of a mixture classified as germ cell mutagens that trigger classification of the mixture

Ingredient classified as:	Concentration limits triggering classification of a mixture as:		
	Category 1A mutagen	Category 1B mutagen	Category 2 mutagen
Category 1A mutagen	≥ 0,1 %	-	-
Category 1B mutagen	-	≥ 0,1 %	-
Category 2 mutagen	-	-	≥ 1,0 %

Note. The concentration limits in the table above apply to solids and liquids (w/w units) as well as gases (v/v units).

3.5.3.2. Classification of mixtures when data are available for the complete mixture

3.5.3.2.1. Classification of mixtures will be based on the available test data for the individual ingredients of the mixture using concentration limits for the ingredients classified as germ cell mutagens. On a case-by-case basis, test data on mixtures may be used for classification when demonstrating effects that have not been established from the evaluation based on the individual ingredients. In such cases, the test results for the mixture as a whole must be shown to be conclusive taking into account dose and other factors such as duration, observations, sensitivity and statistical analysis of germ cell mutagenicity test systems. Adequate documentation supporting the classification shall be retained and made available for review upon request.



3.5.3.3 Classification of mixtures when data are not available for the complete mixture: bridging principles

3.5.3.3.1. Where the mixture itself has not been tested to determine its germ cell mutagenicity hazard, but there are sufficient data on the individual ingredients and similar tested mixtures (subject to paragraph 3.5.3.2.1), to adequately characterise the hazards of the mixture, these data shall be used in accordance with the applicable bridging rules set out in section 1.1.3.

### 3.5.4. Hazard communication

3.5.4.1. Label elements shall be used in accordance with Table 3.5.3, for substances or mixtures meeting the criteria for classification in this hazard class.

Table 3.5.3. Label elements of germ cell mutagenicity

Classification	Category 1A or Category 1B	Category 2
GHS Pictograms		
Signal word	Danger	Warning
Hazard Statement	H340: May cause genetic defects (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard)	H341: Suspected of causing genetic defects (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard)
Precautionary Statement Prevention	P201, P202, P281	P201, P202, P281
Precautionary Statement Response	P308 + P313	P308 + P313
Precautionary Statement Storage	P405	P405
Precautionary Statement Disposal	P501	P501

3.5.5. Additional classification considerations

It is increasingly accepted that the process of chemical-induced tumorigenesis in humans and animals involves genetic changes for example in proto-oncogenes and/or tumour suppresser genes of somatic cells. Therefore, the demonstration of mutagenic properties of substances in somatic and/or germ cells of mammals in vivo may have implications for the potential classification of these substances as carcinogens (see also Carcinogenicity, section 3.6, paragraph 3.6.2.2.6).



## E classification system on carcinogenicity

In 2010, the Committee published a guideline for classifying substances in terms of their carcinogenic properties, and for assessing their genotoxicity.<sup>26</sup> The classification on carcinogenic properties is based on the Globally Harmonized System, which is also used by the European Union for the classification, labelling and packaging of substances and mixtures (Regulation EC 1272/2008, Section 3.6 Carcinogenicity).<sup>25</sup>

The Committee expresses its conclusions in standard phrases:

Category	Judgement by the Committee	Comparable with EU Category
1A	<p><i>The compound is known to be carcinogenic to humans.</i></p> <ul style="list-style-type: none"> <li>• It acts by a stochastic genotoxic mechanism.</li> <li>• It acts by a non-stochastic genotoxic mechanism.</li> <li>• It acts by a non-genotoxic mechanism.</li> <li>• Its potential genotoxicity has been insufficiently investigated. Therefore, it is unclear whether the compound is genotoxic.</li> </ul>	1A
1B	<p><i>The compound is presumed to be as carcinogenic to humans.</i></p> <ul style="list-style-type: none"> <li>• It acts by a stochastic genotoxic mechanism.</li> <li>• It acts by a non-stochastic genotoxic mechanism.</li> <li>• It acts by a non-genotoxic mechanism.</li> <li>• Its potential genotoxicity has been insufficiently investigated. Therefore, it is unclear whether the compound is genotoxic.</li> </ul>	1B
2	<i>The compound is suspected to be carcinogenic to man.</i>	2
(3)	<i>The available data are insufficient to evaluate the carcinogenic properties of the compound.</i>	not applicable
(4)	<i>The compound is probably not carcinogenic to man.</i>	not applicable



## F reliability testing of animal and in vitro studies

To assess the reliability of animal and in vitro studies, the Committee uses the criteria set by Klimisch et al. 1997.<sup>27</sup> A summary of the criteria of the reliability scores is given below. Only studies with a reliability score of 1 or 2 are considered in assessing genotoxicity and carcinogenicity.

### **Reliability 1 (reliable without restriction)**

For example, guideline study (OECD, etc.); comparable to guideline study; test procedure according to national standards (DIN, etc.).

### **Reliability 2 (reliable with restrictions)**

For example, acceptable, well-documented publication/study report which meets basic scientific principles; basic data given: comparable to guidelines/standards; comparable to guideline study with acceptable restrictions.

### **Reliability 3 (not reliable)**

For example, method not validated; documentation insufficient for assessment; does not meet important criteria of today standard methods; relevant methodological deficiencies; unsuitable test system.

### **Reliability 4 (not assignable)**

For example, only short abstract available; only secondary literature (review, tables, books, etc.).



## G reliability testing of epidemiological studies

To assess the reliability of epidemiological studies, the Committee uses the criteria set by Money et al.(2013).<sup>28</sup> A summary of the reliability categories set by Money et al. (2013) is given below. Only studies with a reliability score of 1 or 2 are considered in assessing genotoxicity and carcinogenicity.

### Reliability 1 (reliable without restriction)

#### *Chronic, non-specific outcomes*

Appropriate study design to research question.

- (1) Selected subjects or persons at risk represent appropriate exposure distributions. Adequate procedures of follow-up and reduction of loss to follow up were performed.
- (2) Exposure assessment was made independent of outcome with validated methods, preferentially with individual exposure data.
- (3) Effect data were collected independently from exposure status, using standardized data collection procedures/registries.
- (4) The possibility of serious bias has been reduced by design, controlled through statistical adjustment, and/or quantified through sensitivity analyses.

(5) The sample/exposure range was sufficient to study the question under investigation, so that effects estimates are not constrained by high imprecision.

(6) The data were analysed using appropriate statistical techniques to address the research questions and model assumptions.

(7) The methodology and results were comprehensively and transparently reported according to relevant guidelines (e.g., the STROBE guidelines for observational data, Von Elm et al. 2007).<sup>29</sup>

#### *Acute or specific outcomes*

The same principles should be applied as for chronic, non-specific outcomes. The focus lies more with how well exposure has been characterised, and the disease outcome is defined.

### Reliability 2 (reliable with restrictions)

#### *Chronic, non-specific outcomes*

Applies to studies which possess most of the qualities of studies with reliability 1. The overall quality is comprised due to minor, but obvious, methodological limitations. Examples include well-designed and conducted studies, but with limited measurement data, possibility of some residual confounding, some imprecision due to small sample size or low exposure range.



*Acute or specific outcomes*

The same principles should be applied as for chronic, non-specific outcomes. Examples of shortcomings may include a lack of individual exposure data, and effects derived from self-reported outcomes.

Note: some studies with serious methodological limitations may provide reliable information for an acute or specific outcome.

**Reliability 3 (not reliable)**

The studies fail to meet one or more of the most basic standards necessary to interpret epidemiologic research, such as appropriate study

design to the research question. Shortcomings may include using census job titles as a surrogate for exposure.

**Reliability 4 (not assignable)**

This includes studies or data which do not give sufficient details about methodology used, or which are short listed in abstracts or secondary literature.



## Committee

The membership of the Subcommittee on Classifying Carcinogenic Substances for the evaluation of the genotoxicity and carcinogenicity of occupational exposure during coal gasification:

- H.P.J. te Riele, Professor of molecular biology, VU University Amsterdam, and Netherlands Cancer Institute, Amsterdam, *chairman*
- P.J. Boogaard, Professor of environmental health and human biomonitoring, Wageningen University and Research Centre, and toxicologist, SHELL International BV, The Hague
- M.J.M. Nivard, Molecular biologist and genetic toxicologist, Leiden University Medical Center, Leiden
- E. de Rijk, Toxicologic pathologist, Charles River Laboratories, 's Hertogenbosch
- J.J. Vlaanderen, Epidemiologist, Institute for Risk Assessment Sciences, Utrecht
- J. van Benthem, Genetic toxicologist, RIVM, Bilthoven, *structurally consulted expert*

## Observer

- M. Woutersen, Bureau REACH, RIVM, Bilthoven

## Scientific secretary

- J.M. Rijnkels, The Health Council of the Netherlands, The Hague





The Health Council of the Netherlands, established in 1902, is an independent scientific advisory body. Its remit is “to advise the government and Parliament on the current level of knowledge with respect to public health issues and health (services) research...” (Section 22, Health Act).

The Health Council receives most requests for advice from the Ministers of Health, Welfare and Sport, Infrastructure and Water Management, Social Affairs and Employment, and Agriculture, Nature and Food Quality. The Council can publish advisory reports on its own initiative. It usually does this in order to ask attention for developments or trends that are thought to be relevant to government policy.

Most Health Council reports are prepared by multidisciplinary committees of Dutch or, sometimes, foreign experts, appointed in a personal capacity. The reports are available to the public.

This publication can be downloaded from [www.healthcouncil.nl](http://www.healthcouncil.nl).

Preferred citation:

Health Council of the Netherlands. Emission during coal gasification. Evaluation of the carcinogenicity and genotoxicity. The Hague: Health Council of the Netherlands, 2019; publication no. 2019/07.

All rights reserved

